Welcome to our dedicated page for Voyager Acquisition SEC filings (Ticker: VACH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Voyager Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Voyager Acquisition's regulatory disclosures and financial reporting.
Voyager Acquisition Corp. reported first-quarter 2026 results as a pre‑combination SPAC, with total assets of $272.3 million, almost entirely in a Trust Account invested in a money market fund.
Net income was $180,498 for the three months ended March 31, 2026, driven by $2.37 million of income from investments held in the Trust Account, partly offset by $2.19 million of general and administrative expenses.
The planned business combination with Veraxa Biotech AG advanced: the Form F‑4 was declared effective and shareholders approved the transaction, with implied merger consideration of approximately $1.35 billion. However, approximately 25,217,315 Class A shares, or about 99.67% of public shares, elected redemption, leaving an estimated 82,685 public shares and about $885,556 expected to remain in the Trust Account after paying redemptions. Voyager ended the quarter with cash of $32,790 outside the Trust Account and a working capital deficit of $3.29 million, and management disclosed substantial doubt about its ability to continue as a going concern absent completion of the business combination or additional financing.
Voyager Acquisition Corp. Schedule 13G/A amendment reports that the Magnetar reporting group holds 0 shares and is deemed to beneficially own approximately 0% of Class A ordinary shares as of March 31, 2026. The filing cites approximately 25,300,000 Shares outstanding per the issuer's Form 10-K filed March 10, 2026. The amendment is signed under a joint filing agreement and power of attorney dated in the exhibit list and is dated May 18, 2026.
Voyager Acquisition Corp. Schedule 13G/A Amendment No. 4: joint filers from First Trust report beneficial ownership stakes in the issuer as of 03/31/2026.
The filing states First Trust Merger Arbitrage Fund (VARBX) holds 505,248 shares (1.60%) and that First Trust Capital Management L.P., First Trust Capital Solutions L.P. and FTCS Sub GP LLC collectively report 624,917 shares (2.47%). The filing clarifies sole voting and dispositive power for the reported amounts and is signed on 05/15/2026.
Voyager Acquisition Corp. notified the SEC on a Form 12b-25 that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The delay is attributed to additional time needed to complete financial statements and related disclosures tied to the registrant's pending business combination with Veraxa Biotech AG and the independent accountant's review.
The company states the original filing date for smaller reporting companies was May 15, 2026 and anticipates filing the Quarterly Report no later than the fifth calendar day following the prescribed due date. The registrant disclosed net income of approximately $180,499 for the three months ended March 31, 2026, down from approximately $2,433,145 for the prior-year quarter, driven primarily by higher general and administrative expenses related to the pending business combination. Holders of approximately 99.67% of outstanding Class A ordinary shares exercised redemption rights during the quarter.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amendment to a Schedule 13G regarding holdings of VOYAGER ACQUISITION CORP Class A ordinary shares (CUSIP G93A7H104). The amendment reports 683,732 shared voting and dispositive shares, representing 2.7% of the class as shown on the cover pages. The filing is a joint filing under a signed Joint Filing Agreement and attributes the reported securities to Goldman Sachs Reporting Units; certain client accounts and other entities are expressly disclaimed. Signature dates on the amendment are 04/17/2026 and the cover shows an item date of 03/31/2026.
Voyager Acquisition Corp. ownership amendment: W. R. Berkley Corporation reports beneficial ownership of 1,303,583 Class A ordinary shares of Voyager Acquisition Corp. representing 5.2% of the class. The holding is shown as shared voting and dispositive power of 1,303,583 shares. The filing lists a CUSIP of G93A7H104 and includes signatures dated 05/07/2026.
Voyager Acquisition Corp. received an amended Schedule 13G/A from Wolverine Asset Management, Wolverine Holdings, Christopher L. Gust and Robert R. Bellick reporting 0 Class A Ordinary Shares and 0% beneficial ownership of the issuer's Class A Ordinary Shares. The filing lists the issuer's address as 131 Concord Street, Brooklyn, NY 11201 and shows signatures dated 04/14/2026.
Voyager Acquisition Corp. filed Amendment No. 1 to its annual report for the year ended December 31, 2025. The sole purpose of this amendment is to add Exhibit 97.1, the company’s Policy on Recoupment of Incentive Compensation, which was adopted as of March 10, 2025 and was inadvertently omitted previously.
The company states that no other changes have been made, and the original annual report continues to speak as of, and for, the periods it covers. As context, the aggregate market value of outstanding Class A ordinary shares held by non‑affiliates was $263 million as of June 30, 2025, and there were 25,300,000 Class A ordinary shares and 6,325,000 Class B ordinary shares outstanding as of March 10, 2026.
Voyager Acquisition Corp. held an extraordinary general meeting and its shareholders approved the Business Combination Agreement to effect a multi-step merger with Veraxa Biotech AG and related corporate steps as described in the agreement.
The record date was February 13, 2026; holders representing 21,743,532 Shares (approximately 68.754% of 31,625,000 issued and outstanding Shares) were present in person or by proxy. Shareholders also approved the Initial Merger, an NTA amendment, four non-binding PubCo charter governance proposals, and an adjournment proposal. In connection with the Meeting, holders of 25,217,315 SPAC Class A Ordinary Shares exercised redemption rights; approximately $885,556 will remain in the trust account, subject to further reversal requests.
Voyager Acquisition Corp. shareholders approved its business combination with VERAXA Biotech AG and related merger and charter proposals at a March 12, 2026 meeting. Holders of 25,217,315 Class A shares, representing approximately 99.67% of the Class A shares outstanding, exercised redemption rights. Assuming these elections are not withdrawn, about $885,556 will remain in the trust account and 82,685 Class A shares will convert into shares of the combined company, Veraxa Biotech Holding AG, which is expected to trade on Nasdaq under the symbol VRXA once closing conditions and listing approvals are satisfied.